

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/786,549	03/07/2001	Jorg Priewe	SCH 1705	3734	
23599 7	590 12/24/2002				
MILLEN, WHITE, ZELANO & BRANIGAN, P.C. 2200 CLARENDON BLVD. SUITE 1400			EXAMINER		
			WARE, TODD		
ARLINGTON, VA 22201			ART UNIT	PAPER NUMBER	
			1615		
•			DATE MAILED: 12/24/2002	DATE MAILED: 12/24/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

•	Application No.	Applicant(s)				
	09/786,549	PRIEWE ET AL.				
Office Action Summary	Examiner	Art Unit				
	Todd D Ware	1615				
The MAILING DATE of this communication app		orrespondence address				
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE						
1) Responsive to communication(s) filed on 10-7-02						
`						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4)⊠ Claim(s) 1/2.4.4.16 is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)☑ Claim(s)/②/4/4/fis/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner. ————————————————————————————————————						
10) The drawing(s) filed on is/are: a) accept						
Applicant may not request that any objection to the						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a)☑ All b)☐ Some * c)☐ None of:						
1 Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)				

Page 2

Application/Control Number: 09/786,549

Art Unit: 1615

DETAILED ACTION

Receipt of amendment filed 11-7-02 is acknowledged. Claims 3 and 15 have been canceled and claims 1-2 and 4-14 have been amended as requested and new claims 16-19 have been added. Claims 1-2, 4-14, and 16-19 are pending. In view of the new grounds for rejection, this action is "non-final."

Claim Rejections - 35 USC § 103

- 1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 2. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).
- 3. Claims 1-2, 4-5, 8-10, 12-14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Goldstein et al (6,143,037; hereafter '037).

Application/Control Number: 09/786,549

Art Unit: 1615

- 4. '037 teaches medical devices such as stents coated with a butyl ester cyanoacrylate polymer where the polymer is applied to the stents by dipping the medical device in a solution of the polymer. '037 also discloses that proteins are applied to the device.
- 5. Claim 6-7, 11, and 16-19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Goldstein et al (6,143,037; hereafter '037) in view of Clark et al (6,143,352; hereafter '352).
- 6. '037 teaches medical devices such as stents coated with a butyl ester cyanoacrylate polymer where the polymer is applied to the medical device by dipping the medical device in a solution of the polymer. '037 also discloses that proteins are applied to the device.
- 7. '352 teaches medical devices coated with either a butyl ester cyanoacrylate polymer or a methylene malonic acid ester where the polymer is applied to the medical device by dipping the medical device in a solution of the polymer. '352 also discloses that proteins and calcium carbonate are applied to the device and that the coating compositions are sterilized.
- 8. Accordingly, it would have been obvious to one skilled in the art at the time of the invention to combine '037 and '352 with the motivation of regulating the pH of an environment at a range at which the polymer's in vivo biodegradation occurs at a different rate than it does at physiological pH to provide controlled release.

 Furthermore, the application with a sterilized coating composition to a stent by dipping

Application/Control Number: 09/786,549

Art Unit: 1615

the stent into the sterile solution of polymer with the motivation of avoiding infection in the subject treated with the stent.

Response to Arguments

9. Applicant's arguments with respect to claims 1-2, 4-14, and 16-19 have been considered but are most in view of the new ground(s) of rejection.

Conclusion

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Todd D Ware whose telephone number is (703) 305-1700. The examiner can normally be reached on M-F, 8:30 AM - 5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page can be reached on (703)308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1234.

THURMAN K. PAGE
SUPERVISORY PAYENT EXAMINER

Page 4

tw

December 19, 2002